Last updated: February 14, 2026
Overview
NDC 00555-0953 is a medication marketed under the name Campral (acamprosate calcium). It is approved by the FDA for alcohol dependence management. This report provides an evaluation of current market conditions, competitive landscape, and future pricing trends.
Current Market Landscape
Campral's market primarily involves addiction treatment centers, outpatient clinics, and healthcare providers managing alcohol use disorder (AUD). The U.S. market size for AUD treatment drugs was approximately $1.2 billion in 2022, with Campral accounting for about 20% of prescriptions among approved medications, which include disulfiram, naltrexone, and acamprosate.
Prescription trends have been steady, with approximately 1 million prescriptions dispensed annually in the U.S. (IQVIA, 2022). No significant patent exclusivity restrictions exist post-exclusivity period, leading to increased generic competition.
Price and Cost Analysis
-
BrandName Campral: Historically, the wholesale acquisition cost (WAC) has been approximately $6.00 per 333 mg tablet. Monthly treatment, assuming three tablets daily, sums to roughly $540 per patient.
-
Generic Acamprosate: Post-patent expiry, generics entered the market at 40-60% of the brand's price, roughly $2.50 to $3.60 per tablet. This has led to a significant reduction in patient out-of-pocket costs and overall market prices.
-
Reimbursement and Insurance Impact: Reimbursement rates for brand versus generic vary by plan but generally favor generics, further accelerating generic adoption.
Price Projection Analysis
-
Short-term (1-2 years): Given patent expirations and increased generic supply, expect prices for acamprosate to stabilize around $2.50-3.00 per tablet. Brand prices are likely to decline further as generic market share increases.
-
Medium-term (3-5 years): Market penetration by generics could further drive prices down by 10-15%. Innovations or new formulations are unlikely within this period, maintaining downward pressure.
-
Long-term (>5 years): Market saturation may lead to stabilized prices, with potential for small increases due to inflation or changes in healthcare policy, but substantial price hikes are unlikely absent new patent protections or formulations.
Competitive Dynamics
-
Main competitors include naltrexone (Vivitrol, Revia) and disulfiram (Antabuse). These drugs vary in administration route and patient acceptance but compete directly in the AUD treatment space.
-
The competitive landscape favors generics, decreasing the potential for significant brand price increases.
Regulatory and Policy Factors
-
FDA approval for new formulations or delivery mechanisms is limited; thus, price elasticity depends primarily on generic competition and healthcare policies promoting generic use.
-
Policies incentivizing cost-effective treatments could further suppress prices, especially in government-funded programs like Medicaid or Medicare.
Key Market Drivers
-
Increasing recognition of AUD as a chronic disease.
-
Growing insurance coverage for medication-assisted treatment (MAT).
-
Heightened emphasis on reducing healthcare costs.
Summary of Price Trends
| Timeline |
Expected Price Range per Tablet |
Key Drivers |
| 2023-2024 |
$2.50 - $3.00 |
Generic competition, market saturation |
| 2025-2027 |
$2.30 - $2.80 |
Continued market share shift, policy influence |
| 2028+ |
Stabilized around $2.20 - $2.50 |
Market saturation, healthcare policies |
Key Considerations
-
The impact of biosimilar or alternative formulations is minimal due to existing generic options.
-
Price projections exclude potential supply chain disruptions or regulatory changes that could alter market dynamics.
References
-
IQVIA, Prescription Data Reports, 2022.
-
FDA Drug Approvals and Patent Data, 2022-2023.
-
MarketWatch, "Alcohol Dependence Treatment Market," 2022.
-
Authors' analysis based on historical pricing and market data.
Key Takeaways
-
NDC 00555-0953 (Campral) faces increasing generic competition, with prices expected to decline further.
-
Current prices hover around $2.50-3.00 per tablet; market pressures suggest continuation of this trend.
-
The AUD market is growing steadily, providing sustained demand despite pricing pressures.
-
Policy and insurance coverage heavily influence pricing and accessibility.
-
Innovations or new formulations are unlikely to impact pricing within the next five years.
FAQs
1. How does the pricing of Campral compare to other AUD treatments?
Campral’s generic prices are comparable or slightly higher than alternative medications like disulfiram, but it competes through its efficacy profile and safety.
2. Are there upcoming patent protections that could affect prices?
No; the original patent expired, and generics dominate the market, limiting price increases.
3. Will insurance coverage impact future pricing?
Yes; increased insurance coverage for generics encourages use, further pressuring prices downward.
4. How does international pricing compare?
International prices vary but generally align with U.S. generic prices, often lower due to different healthcare systems.
5. What factors could disrupt current price trends?
Regulatory changes, supply chain issues, or new formulations could alter current market dynamics.
[1] IQVIA Prescription Data 2022
[2] FDA patent database, 2023
[3] MarketWatch, 2022
[4] Industry analysis reports
